Horizon Eye Care Offers the First & Only FDA-Approved Cross-linking Therapy for Treatment of Progressive Keratoconus




For patients living with keratoconus, a progressive thinning and weakening of the cornea, which can result in significant visual loss and may lead to corneal transplant, Horizon Eye Care is proud  to offer a new therapeutic treatment, corneal cross-linking. With corneal cross-linking, the progression of keratoconus is slowed down or halted, and it may eliminate the need for a corneal transplant.

Photo of woman with ketatocunus Horizon Eye Care is the only eye care practice in the region with this advanced technology. Three of Horizon’s skilled physicians – Drs. Joseph Biber, and Gerald Rosen – are qualified to perform Avedro’s corneal cross-linking procedure.

Corneal cross-linking is beneficial to our patients in that if offers them a therapeutic option to limit the progression of keratoconus and ectasia,” says Dr. Gerald Rosen. “The FDA approval of corneal cross-linking with Photrexa products and the KXL System offers new treatment options for appropriate patients who, until now, had few options to help with their vision challenges and no way therapeutic treatment for these sight-threatening conditions.”

In keratoconus patients, the typically round, dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge that produces optical irregularities that affect vision. A rare condition, keratoconus typically appears in individuals who are in their late teens or early twenties. Early symptoms include blurring or distortion of vision or increased sensitivity to light. Corneal ectasia, also marked by progressive corneal steepening and thinning, is a rare but serious complication resulting from vision correction procedures – such as laser-assisted in-situ keratomileusis (LASIK) and photorefractive keratectomy (PRK), and is associated with worsening vision.

Corneal cross-linking using Avedro’s Photrexa products and KXL System is a medical procedure that combines the use of ultra-violet (UV) light and riboflavin (vitamin B2) eye drops. The procedure works by creating new corneal collagen cross-links, which results in a shortening and thickening of collagen fibrils that leads to the stiffening the cornea. Cross-linking, which has been performed in Europe since 2003, is considered the standard of care around the world for keratoconus and corneal ecstasia following refractive surgery.

“Early diagnosis is critical and allows patients to be treated at the onset of the disease,” added Dr. Rosen. “Patients suffering from progressive keratoconus and corneal ectasia following refractive surgery can now receive a therapeutic treatment that has been rigorously tested and approved.”

To determine if you are a candidate for this minimally invasive, outpatient procedure ask your Horizon Eye Care physician or call 704-365-0555 to set up a consultation. Or, request an appointment here, right now.

<< Return to main Blog page

AESTHETIC
CENTER
LEARN MORE
CATARACT
CENTER
LEARN MORE
CLEAR LENS EXCHANGE | REFRACTIVE LENS EXCHANGE
CENTER
LEARN MORE
CORNEA
CENTER
LEARN MORE
DRY EYE
CENTER
LEARN MORE
EYE EXAM
CENTER
LEARN MORE
GLAUCOMA
CENTER
LEARN MORE
LASIK
CENTER
LEARN MORE
PEDIATRIC
CENTER
LEARN MORE
RETINA
CENTER
LEARN MORE